Real-world data has never been more abundant, but data alone doesn’t tell the full patient story. In this episode of tHEORetically Speaking, Becky Hollenberg, Senior Real-World Data Strategy Lead at
AI is no longer a peripheral tool in drug development. It is reshaping how trials are designed, run, and completed, and the pace of change is accelerating. In this episode
T1D Exchange published research in Diabetes Technology & Therapeutics using NorstellaLinQ lab data linked to their T1D patient registry and wearable device data. The objective of the study was to
This webinar explores how real-world data (RWD) and AI are transforming clinical development, evidence generation, and commercialization, particularly in rare diseases and brain cancer. Speakers discuss how integrated RWD helps
This webinar explores how integrated real-world data (RWD) and AI are reshaping commercial strategy for GLP-1 therapies as the obesity and cardiometabolic markets rapidly expand. Speakers discuss how combining EMR,
This pharmaphorum podcast explores how AI is transforming drug development and commercialization, with Norstella Chief Product Officer Kris Kaneta discussing
Drug development has made huge scientific progress over the last decade. The way we run clinical development has changed far
For GLP-1 therapies, traditional data sources alone aren’t enough to understand the full patient journey. NorstellaLinQ’s 74 billion data points
Norstella recently spoke with the Wall Street Journal’s Brian Gormley in a feature article: Biotech VC’s Vaccine Die-Hards. The piece
Rare Disease Day will be commemorated on 28 February this year, as it has been every year since 2008. Coordinated
In the first few weeks following the launch of oral semaglutide, early prescription activity answered a familiar question: Uptake was
Stop by Booth 1034 to see live demos of our AI capabilities and meet the experts who are building and deploying pharma intelligence at scale.
